Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation
· Idefirix[®] is granted full access and reimbursement in line with the indication approved by the European Medicines Agency (EMA).[1] · The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix[®] to enable kidney transplantation.Lund, Sweden, December 8, 2022. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that the Italian Medicine Agency (AIFA) has granted full access and reimbursement for the use of Idefirix[®], the